GlassScriptPhysician profile
Ronald W Johnson
NPI 1134128028
$10,393.05
in general payments reported to CMS, 2019-2025
33 companies · $931 in 2025
The $931 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,053 · 2020: $614 · 2021: $1,151 · 2022: $1,037 · 2023: $2,753 · 2024: $854 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,446 · Education: $91.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,445.74 |
| Education | $91.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,127.30 | 2019-2025 | Evenity, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $1,637.40 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,123.01 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $890.52 | 2019-2025 | |
| Glaxosmithkline, LLC. | $650.23 | 2019-2023 | Arexvy |
| Abbvie INC. | $579.81 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $435.27 | 2021-2024 | |
| Lilly USA, LLC | $390.77 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Allergan, INC. | $288.04 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $224.74 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.88 | 2019-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $170.90 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $170.30 | 2023 | Nuzyra |
| Corium, LLC | $163.20 | 2022-2023 | Azstarys |
| Merck Sharp & Dohme LLC | $162.28 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $145.44 | 2019 | |
| Medtronic, INC. | $137.87 | 2023 | Intellis Adaptivestim |
| Phathom Pharmaceuticals, INC. | $137.61 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $125.00 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $115.89 | 2021 | |
| Astellas Pharma US INC | $108.74 | 2023 | Myrbetriq, Veozah |
| Dexcom, INC. | $95.42 | 2023-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $62.15 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.96 | 2019-2020 | |
| Exact Sciences Corporation | $47.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $42.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $37.43 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.01 | 2023 | Gvoke Hypopen |
| Eisai INC. | $16.78 | 2020 | |
| Sunovion Pharmaceuticals INC. | $15.28 | 2019 | |
| Organon LLC | $13.91 | 2023 | Nexplanon |
| Kowa Pharmaceuticals America, INC. | $12.91 | 2023 | Livalo, Seglentis |
| Abbott Laboratories | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.